This inventor holds 7 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 3 EPO patents. Top assignees: Korea Institute of Science and Technology, Cureverse Incorporated, Industry-Academic Cooperation Foundation of Sunchon National University. Active years: 2018-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2018-2026
Title: Sang Min Lim: Innovator in Pharmaceutical Chemistry
Introduction
Sang Min Lim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds aimed at treating neurodegenerative diseases.
Latest Patents
Sang Min Lim holds two notable patents. The first patent is for a novel halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative and its use. This invention relates to a preparation method and includes an Nrf2 activator, which is crucial for preventing or treating diseases caused by decreased Nrf2 activity. The second patent involves a levosimendan compound, which is used for preventing or treating tau-related diseases, including neurodegenerative conditions such as Alzheimer's disease. This patent also encompasses health functional foods that contain the levosimendan compound.
Career Highlights
Throughout his career, Sang Min Lim has worked with notable organizations, including Cureverse Incorporated and the Korea Institute of Science and Technology. His work has focused on innovative solutions in the pharmaceutical sector, contributing to advancements in medical treatments.
Collaborations
Sang Min Lim has collaborated with esteemed colleagues, including Ae Nim Pae and Ki Duk Park. These partnerships have fostered a collaborative environment that enhances research and development in his field.
Conclusion
Sang Min Lim's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a key inventor in the industry. His work continues to pave the way for advancements in treatments for neurodegenerative diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile